Skip to main content
Neurocrine Biosciences
2026-06-11 Neurocrine Biosciences' approved medicines include INGREZZA® and CRENESSITY™ for patients in the United States.

Approved Medicines

Products

The Product Information provided below is intended for residents of the U.S. only.

INGREZZA® (valbenazine) INGREZZA® capsules
Full Prescribing Information, Including Boxed Warning Medication Guide Visit INGREZZA.com for More Information
CRENESSITY™ (crinecerfont)
Full Prescribing Information Visit CRENESSITY.com for More Information
VYKATXR
Full Prescribing Information Medication Guide Visit VYKATXR.com for More Information

Neurocrine Biosciences/AbbVie Collaboration

After discovering and developing elagolix through Phase 2 studies in endometriosis, we out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix. AbbVie launched ORILISSA® (elagolix tablets) in the United States and Canada in August and November 2018, respectively.

In June 2020, AbbVie launched ORIAHNN® (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States. We receive royalties at tiered percentage rates on AbbVie net sales of products containing elagolix.

ORILISSA® (elagolix)
Learn more about ORILISSA®

Links to a website owned by AbbVie Inc.

ORIAHNN® (elagolix, estradiol and norethindrone acetate)
Learn more about Oriahnn®

Links to a website owned by AbbVie Inc.